A year in Oncology

A Review of 2020 Drug Approvals & Key Milestones

Despite a global pandemic, 2020 saw a notable number of approvals of new anti-cancer therapies in the US, Europe and Japan – including the continued roll-out of immuno-oncology (I-O) therapies.

The US saw a similar number of new oncology drug/indication approvals in 2020 as in 2019. An even higher number were seen in Japan, largely due to approvals ahead of all other global regions (as per the Sakigake Designation Scheme) and the rollout of drugs already sanctioned by the FDA. In Europe, however, there were around a quarter fewer approvals in 2020 than in the prior year.

To view the approvals and the key milestones (in our view) in an easy-to-digest snapshot, please see Ipsos’ infographic, ‘A Year in Oncology: A Review of 2020 Drug Approvals in US, Europe & Japan’.

 

Related news

  • [Webinar] KEYS: Battle For Attention
    Communication Events replay

    [Webinar] KEYS: Battle For Attention

    In an era dominated by ad-skipping, multi-screening, and media fragmentation, the challenge for today’s marketer is no longer just “Who am I reaching?” but “Am I reaching them at all?"
  • Where is metabolic medicine heading
    Healthcare Events replay

    Where is metabolic medicine heading – and what do you need to know?

    What happens when pipeline promise becomes market reality? During this PBSS webinar, Scott Morano and Roberto Cortese expertly guide viewers through the recent transformations in metabolic therapeutics for obesity, diabetes and MASH, and where the field is heading next.
  • KEYS: Screen time
    Media Measurement Events replay

    [WEBINAR] KEYS: Screen time

    At our first KEYS webinar of the year we’ll be looking at what’s really happening on screens these days. What’s changing? What’s enduring? And how can businesses do better when it comes to engaging with people on their screens, in real time?